<DOC>
	<DOCNO>NCT00054288</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine irinotecan gemcitabine treat patient refractory advanced solid tumor .</brief_summary>
	<brief_title>Irinotecan Gemcitabine Treating Patients With Refractory Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose irinotecan administer gemcitabine patient refractory advanced solid tumor . - Determine antitumor activity toxicity regimen patient . - Determine pharmacokinetics pharmacodynamics regimen patient . - Determine optimal dose time interval regimen patient . OUTLINE : This open-label , non-randomized , dose-escalation study irinotecan . Patients receive irinotecan IV 90 minute day 1 8 gemcitabine IV 30 minute day 2 9 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 8 week . PROJECTED ACCRUAL : A total 24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor refractory prior treatment Considered incurable modality Measurable evaluable disease The following consider measurable evaluable : Bone metastases Pleural , pericardial , peritoneal effusion Irradiated lesion ( unless progression document radiotherapy ) Metastatic disease follow use serum tumor marker allow No symptomatic brain metastasis Brain metastasis may sole site metastatic disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy At least 12 week Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic AST ALT great 1.5 time normal Bilirubin great 1.5 mg/dL No clinically apparent jaundice Renal Creatinine great 1.6 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular Cardiac function normal No uncontrolled heart disease No myocardial infarction within past 3 month No congestive heart failure No unstable uncontrolled angina Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No active infection require systemic therapy No uncontrolled seizures No uncontrolled diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior gemcitabine No prior camptothecin compound Prior irinotecan allow No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 14 day since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 30 day since prior clinical trial participation No concurrent investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>